SBIR-STTR Award

Thermally Activatable Probes And Cofactors For Hot Start Ligase Chain Reaction
Award last edited on: 11/11/11

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$99,462
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Alexandre Lebedev

Company Information

TriLink BioTechnologies Inc (AKA: TriLink)

9955 Mesa Rim Road
San Diego, CA 92121
   (858) 546-0004
   info@trilinkbiotech.com
   www.trilinkbiotech.com
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: 1R43GM093562-01A1
Start Date: 1/15/11    Completed: 1/14/12
Phase I year
2011
Phase I Amount
$99,462
The Ligase Chain Reaction (LCR) is a DNA amplification technique that can either be utilized in conjunction with Polymerase Chain reaction (PCR), or as an alternative to PCR, due to its equal ability to support exponential signal amplification. LCR is being used as a tool in molecular biology and diagnostic applications, especially for nucleotide sequence detection and single nucleotide polymorphism (SNP) detection. However, performance problems and non-specificity issues, including the accumulation of false-positive signals, often make conventional LCR an unlikely choice in clinical diagnostics and in the development of ligation-based applications. Herein, we propose a novel Hot Start approach for LCR. Similar to the benefit seen for Hot Start activation methods in PCR, the Hot Start LCR approach is predicted to have substantially improved specificity and performance, compared to conventional LCR. Hot Start LCR employs chemically modified ligation components, including oligonucleotide probes and cofactors, containing thermally labile protecting groups for heat-triggered LCR. We believe that this approach will be a significant improvement to current methods because it has the high potential to replace a number of applications where traditional PCR, Gap-LCR or PCR/ligation combination approaches are either expensive, not applicable, or show problematic performance.

Public Health Relevance:
As of 2009, the molecular diagnostics market has an average annual growth rate of 12- 15%, with an estimated value of $3-3.5 billion worldwide, where $2 to $2.5 billion of the market is in the USA. The Ligase Chain Reaction (LCR) is a substantial component of this market. We propose to improve the specificity of conventional LCR by developing a novel approach that includes Hot Start activation of LCR by using modified oligonucleotide probes and cofactors with thermolabile protecting groups.

Thesaurus Terms:
Adenosine;Ampligase;Base Sequence;Buffers;Cell Communication And Signaling;Cell Signaling;Clinical;Closure By Ligation;Cognitive Discrimination;Complex;Dna;Dna Amplification Technics;Dna Amplification Technique;Dna Joinases;Dna Ligases;Dna Molecular Biology;Deoxyribonucleic Acid;Detection;Development;Diagnostic;Discrimination;Discrimination (Psychology);Enzyme Tests;Evaluation;Event;Generalized Growth;Goals;Government;Growth;Heating;Intracellular Communication And Signaling;Length;Ligase;Ligase Chain Reaction;Ligation;Manuals;Marketing;Methods;Modeling;Modification;Molecular;Molecular Biology;Natural Regeneration;Nucleotide Sequence;Nucleotides;Oligo;Oligonucleotide Probes;Oligonucleotides;Pcr;Performance;Persons;Polydeoxyribonucleotide Ligases;Polydeoxyribonucleotide Synthetases;Polymerase Chain Reaction;Polymorphism Analysis;Polymorphism Detection;Polymorphism, Single Base;Preparation;Protocol;Protocols Documentation;Regeneration;Snp;Snps;Signal Transduction;Signal Transduction Systems;Signaling;Single Nucleotide Polymorphism;Specificity;Synthetases;Temperature;Testing;Time;Tissue Growth;Work;Base;Biological Signal Transduction;Cofactor;Experiment;Experimental Research;Experimental Study;Heat;Improved;Model;New Approaches;Nicotinamide Ribonucleoside;Nicotinamide Ribose;Nicotinamide Riboside;Nicotinamide-Beta-Riboside;Novel;Novel Approaches;Novel Strategies;Novel Strategy;Nucleic Acid Sequence;Ontogeny;Phase 1 Study;Regenerate;Research Study;Sugar;Synthetic Dna;Synthetic Construct;Tool

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----